Argentinian pharma company Biosidus and Crystec have announced a new deal for development of dry powder formulations of Biosidus drugs for inhaled and/or nasal delivery using Crystec's mSAS supercritical fluid particle engineering technology. The first project for the two companies under the new agreement will be development of a dry powder formulation of teriparatide … [Read more...] about Biosidus partners with Crystec on development of dry powder teriparatide for the treatment of osteoporosis
Business
Bayer and Meda file patent infringement suit after Apotex submits ANDA for generic of Astepro Allergy nasal spray
Bayer HealthCare and Meda Pharmaceuticals have filed a patent infringement suit against Apotex after Apotex submitted an ANDA for a generic version of Astepro Allergy azelastine hydrochloride nasal spray, 0.15%. The FDA approved Bayer's NDA for Astepro Allergy for non-prescription treatment of allergic rhinitis in June 2021. According to the complaint filed by Bayer … [Read more...] about Bayer and Meda file patent infringement suit after Apotex submits ANDA for generic of Astepro Allergy nasal spray
US PTAB finds that the majority of the claims in a Tyvaso patent challenged by Liquidia are unpatentable
According to Liquidia Corporation, an inter partes review by the US Patent Trial and Appeal Board (PTAB) regarding US Patent No. 9,604,901, which is listed in the Orange Book as one of 7 patents covering United Therapeutics' Tyvaso inhalation solution, determined that only 2 out of 9 claims included in the patent were potentially patentable based on a review of prior … [Read more...] about US PTAB finds that the majority of the claims in a Tyvaso patent challenged by Liquidia are unpatentable
Glenmark launches Tavulus tiotropium bromide DPI in Spain
Glenmark Pharmaceuticals has announced the launch of its version of Spiriva Handihaler tiotropium bromide DPI in Spain, where it will be known as Tavulus. In August 2018, Glenmark announced that it had acquired the rights to market the tiotropium dry powder inhaler in Western Europe. The company recently launched the tiotropium DPI in the UK, where it is called … [Read more...] about Glenmark launches Tavulus tiotropium bromide DPI in Spain
Oncotelic Therapeutics to develop intranasal apomorphine
Oncotelic Therapeutics (formerly Mateon Therapeutics) announced that it has licensed an intranasal apomorphine formulation from Autotelic, Inc, a newly formed company owned largely by Oncotelic Chairman and CEO, Vuong Trieu. Oncotelic says that it plans to develop AL-101 nasal apomorphine for Parkinson's disease, erectile dysfunction, and female sexual dysfunction, … [Read more...] about Oncotelic Therapeutics to develop intranasal apomorphine
Ryaltris nasal spray gets marketing approval in 13 countries in Europe, UK
Glenmark Pharmaceuticals said that its Ryaltris olopatadine / mometasone furoate nasal spray for the treatment of seasonal and perennial allergic rhinitis has received final marketing approval in 13 countries in Europe and the UK. Earlier this year, the company announced that Ryaltris had received approval in 16 European countries and the UK through the decentralized … [Read more...] about Ryaltris nasal spray gets marketing approval in 13 countries in Europe, UK
COPD Foundation partners with Renovion for development of inhaled mucolytic
The COPD Foundation has partnered with Renovion on development of Renovion's ARINA-1 nebulized glutathione / bicarbonate / ascorbic acid for the treatment of COPD and non-cystic fibrosis bronchiectasis, the foundation said. ARINA-1, which is delivered via the PARI eFlow nebulizer system, received orphan drug designation from the FDA for the treatment of lung … [Read more...] about COPD Foundation partners with Renovion for development of inhaled mucolytic
GSK says it is evaluating new MDI propellant as part of commitment to reducing greenhouse gas emissions
GlaxoSmithKline has announced an initiative to evaluate a new lower global warming potential propellant for its metered dose inhalers as part of an effort to reach net zero carbon emissions. According to GSK, its Ventolin albuterol (salbutamol) MDIs for the rescue treatment of asthma account for 45% of the company's current carbon emissions, and the company expects … [Read more...] about GSK says it is evaluating new MDI propellant as part of commitment to reducing greenhouse gas emissions
Virpax to develop intranasal CBD for the treatment of epilepsy
Virpax says that it has acquired exclusive worldwide rights to Nanomerics's molecular envelope technology (MET) for use with Virpax's VRP324 intranasal dry powder cannabidiol (CBD) for the treatment of epilepsy. According to Virpax, Nanomerics is currently conducting preclinical studies of VRP324, which Virpax plans to develop for the treatment of seizures due to … [Read more...] about Virpax to develop intranasal CBD for the treatment of epilepsy
DDL, BTS announce that they will cut ties with Vectura following PMI acquisition
The Drug Delivery to the Lungs conference organizing committee and the British Thoracic Society have both announced that they will cut ties with inhalation CDMO Vectura following the company's acquisition by tobacco company Philip Morris International. Vectura announced in May 2021 that it would be acquired by the Carlyle Group; however, the company withdrew its … [Read more...] about DDL, BTS announce that they will cut ties with Vectura following PMI acquisition